{"brief_title": "A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer", "brief_summary": "This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.", "condition": ["Prostate Cancer"], "intervention_type": ["Drug"], "intervention_name": ["Atrasentan"], "criteria": "Inclusion Criteria: - Diagnosis of prostate cancer. - Rising PSA while on hormonal therapy or following surgical castration. - Documented evidence of metastatic disease. Exclusion Criteria: - Have received cytotoxic chemotherapy. - Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.", "gender": "Male", "minimum_age": "19 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Hormone-Refractory, Prostate Cancer", "mesh_term": ["Prostatic Neoplasms", "Hormones", "Atrasentan"], "id": "NCT00036543"}